MedTrace Logo

Use of Rosuvastatin in HIV-Infected Subjects to Modulate Cardiovascular Risks

NCT01218802 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 147

Last updated 2016-03-08

Study results available
· View outcomes & findings →

Summary

The hypothesis of this study is that 96 weeks of Rosuvastatin will be safe and effective in decreasing cardiovascular risk and bone loss in the HIV+ population.

Conditions

Interventions

DRUG

Rosuvastatin 10 mg. daily for 96 weeks

Participants will take Rosuvastatin 10 mg. daily for 96 weeks.

DRUG

Placebo

participants will take a sugar pill daily for 96 weeks

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • AstraZeneca

    collaborator INDUSTRY

  • University Hospitals Cleveland Medical Center

    lead OTHER

Principal Investigators

  • Grace McComsey, MD · University Hospitals Cleveland Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2014-05-31
Completion
2014-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01218802 on ClinicalTrials.gov